IBRX · ImmunityBio, Inc.

The thesis

ImmunityBio's bladder-cancer drug Anktiva is growing fast enough to keep supporting the shares, and the next read on that growth is the third-quarter revenue figure. The case turns on whether third-quarter net product revenue beats the second quarter's $50.7 million. The Food and Drug Administration (FDA) decision on a broader label, due by 6 January 2027, is the test after that.

Anktiva's net product revenue rose from about $44.2 million in the first quarter of 2026 (preliminary figure, 8-K of 9 April 2026) to $50.7 million in the second quarter. The second-quarter figure was up 92% year over year and marked the eighth straight quarter of sequential growth, per the company's 4 August 2026 8-K. The company sells an approved product, yet the shares trade like a binary-catalyst name: FDA dates, label news and retail attention move the price more than the broad market does.

The narrative is maturing: the 2 October 2026 rally drew Benzinga coverage and two directors sold into it, and no new company release or filing has appeared since. The shares have steadied since the 6 October 2026 pullback, closing at $9.91 on 8 October 2026, up from $9.69.

Bullish and bearish views on ImmunityBio, Inc.

The bull case on ImmunityBio, Inc. (IBRX), in brief: Eight straight quarters of sequential growth. The bear case: Director Barry J. Most of that notice had not been reported sold as of 6 October 2026.

Bull case

• Eight straight quarters of sequential growth. Q2 2026 net product revenue was $50.7 million, up 15% from Q1, the company's 4 August 2026 8-K shows. First-half revenue was $94.8 million, up 121% year over year.
• The company has reported revenue early before. ImmunityBio published preliminary Q1 2026 revenue of about $44.2 million on 9 April 2026, nine days after the quarter closed, per its 8-K. A similar early release would put a third-quarter number in front of the market in October.
• A label expansion is under FDA review. The FDA accepted a supplemental Biologics License Application (sBLA) for Anktiva plus BCG in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary disease and no carcinoma in situ. The target action date is 6 January 2027, per the 4 August 2026 release.
• More indications are queued. The company plans a fourth-quarter 2026 filing for BCG-naive NMIBC carcinoma in situ, based on the fully enrolled QUILT-2.005 trial. The UAE's Emirates Drug Establishment approved Anktiva on 29 July 2026.
• Analysts mostly rate the shares a buy. Jefferies upgraded the stock to Strong Buy on 25 September 2026. MarketBeat's consensus was Moderate Buy with a $14.20 average target on 6 October 2026, and StockAnalysis counted seven analysts averaging $12.57, from $7 to D. Boral Capital's $23.

Bear case

• Director Barry J.
• Most of that notice had not been reported sold as of 6 October 2026.
• Losses are large against cash. The Q2 2026 GAAP net loss was $230.4 million and the adjusted loss $81.0 million, per the 4 August 2026 8-K.

Price setup

The shares closed at $9.91 on 8 October 2026, 14.2% below the 52-week high of $11.55 in adjusted daily closes. They were up 27.2% over three months. The 14-day relative strength index (RSI) stood at 64.6, below the 70 level often read as overbought, after falling from above 70 earlier in the week.

The late-September run carried the shares through $10, and the 5 October 2026 close of $10.38 marked the most recent high point before directors' sales were reported. The $8.50 level sits below the late-September breakout and would put the shares back toward their 50-day moving average. Crowding is visible in the insider selling into strength and the thin public float, with insiders holding about 66% of shares per MarketBeat.

Catalysts, next 30 days

• ~15 October 2026 (est.) — possible preliminary Q3 2026 revenue. The company released preliminary Q1 figures on 9 April 2026 and preliminary full-year 2025 figures on 15 January 2026. A figure above $50.7 million extends the growth run; a flat or lower figure breaks it.
• ~3 November 2026 (est.) — Q3 2026 report. Earnings Whispers lists 16 November 2026. The report updates cash after the Q2 GAAP loss of $230.4 million and shows the spending trend.
• ~31 December 2026 (est.) — planned sBLA filing in BCG-naive carcinoma in situ. A filing on schedule adds a third label-expansion path.
• 6 January 2027 — FDA target action date for the papillary-disease sBLA. Approval widens Anktiva's label; a rejection removes the main near-term expansion driver.

What would change the view

Third-quarter Anktiva net product revenue at or below Q2's $50.7 million, whether in a preliminary release or the full report, would break the growth case. An equity raise before the 6 January 2027 FDA date, or a complete response letter or review extension on the papillary sBLA, would also undercut it.

On price, a daily close below $8.50 would undo the late-September run through $10. Further Form 4 filings showing Simon selling most of his 560,000-share notice would add supply to a thin float. A preliminary Q3 figure well above $50.7 million with cash holding above $300 million would strengthen the case.

What it trades with

ImmunityBio sits in the precision-biotech group with Kodiak Sciences (KOD), Iovance Biotherapeutics (IOVA), Moderna (MRNA), Schrödinger (SDGR) and Recursion (RXRX). The group's attention cooled to maturing on 9 October 2026 after a brief pickup on 4 October 2026, which raises the bar for single-name moves. Iovance is the closest comparison: a commercial-stage immunotherapy company whose shares also move on launch revenue. IBRX's main drivers are company-specific (Anktiva sales, FDA dates, insider filings), so a group sell-off matters most if it coincides with weak Q3 revenue.